Karyopharm Therapeutics Inc
NASDAQ:KPTI
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.8400
  • TODAY'S CHANGE (%)
    -0.0050 (-0.5917%)
  • Bid / Lots
    0.8400/ 96
  • Ask / Lots
    0.8560/ 90
  • Open / Previous Close
    0.8666 / 0.8450
  • Day Range
    0.8400
    0.8744
  • 52 Week Range
    0.6174
    1.9500
  • Volume
    451,762

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

  • Nov 20, 2024

      Show headlines and story abstract

    • 5:54PM ET on Wednesday Nov 20, 2024 by MT Newswires
      Companies Mentioned: KPTI
      05:54 PM EST, 11/20/2024 (MT Newswires) -- Karyopharm Therapeutics (KPTI) said Wednesday it appointed Kristin Abate as chief accounting officer, starting Wednesday. Abate, who previously was working as interim principal accounting officer, will cont...

    • 4:05PM ET on Wednesday Nov 20, 2024 by PR Newswire
      Companies Mentioned: KPTI

      Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as the Company's interim principal financial officer.

    • 4:05PM ET on Wednesday Nov 20, 2024 by Dow Jones
      Companies Mentioned: KPTI

      Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

      PR Newswire

      NEWTON, Mass., Nov. 20, 2024

      NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as the Company's interim principal financial officer.

Peers Headlines